Stay in Sync with Your Horse

[United States Eventing Association, Inc.]

https://adequan.com/Index
Take the reins on
your horse’s mobility
Whether you’re getting ready for your next dressage competition, show jumping or anything in-between, your horse’s mobility matters. Adequan^® i.m. (polysulfated glycosaminoglycan) is the only FDA-approved PSGAG for arthritis in horses. It is proven to:^1,2
reduce inflammation, restore synovial joint fluid, repair joint cartilage, reverse the disease process
SELECT IMPORTANT SAFETY INFORMATION: There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. See below for Indications and additional Important Safety Information.
https://adequan.com/for-horse-owners
What is arthritis?
Equine arthritis, commonly referred to as osteoarthritis or degenerative joint disease, is a painful disease characterized by progressive deterioration of cartilage and changes in the joint.^3 It can affect horses of any age, breed or discipline. The good news: Adequan i.m. may help slow the effects of the disease, especially if you and your vet catch arthritis early.
Ask your veterinarian if Adequan i.m. can help keep your horse moving.
https://adequan.com/horse-owners/joint-health-in-horses
Adequan^® Canine (polysulfated glycosaminoglycan) can help you enjoy more active years with your best friend. It’s the only FDA-approved cartilage-protecting treatment that helps treat canine arthritis, not just its symptoms.
Ask your veterinarian how Adequan Canine can help keep your dog’s mobility on track.
SELECT IMPORTANT SAFETY INFORMATION: Adequan^® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. See below for Indications and additional Important Safety Information.
https://adequancanine.com/for-pet-parents
Adequan^® i.m. polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL
INDICATIONS Adequan^® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequan.com. (https://adequan.com/)
Adequan^® Canine polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL
INDICATIONS Adequan^® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan^® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequancanine.com. (https://www.adequancanine.com/)
1. Adequan^® i.m. (polysulfated glycosaminoglycan), Package Insert.
American Regent, Inc.
2. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC,
Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703
3. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the
Horse. St. Louis, MO: Elsevier, 2016; 33-48.
Sent on behalf of: American Regent, Inc. 5 Ramsey Rd, Shirley, NY, 11967 US All trademarks are the property of their respective owners. © 2025 American Regent, Inc. PP-AI-US-0857 (v3.0)

This email was sent to drazipurple2011 at gmail.com (mailto:drazipurple2011 at gmail.com)
why did I get this? (https://useventing.us2.list-manage.com/about?u=d07afbf7e3df030bdd8a7c510&id=317a05b795&e=609b4b71a5&c=fdff8126b6)     unsubscribe from this list (https://useventing.us2.list-manage.com/unsubscribe?u=d07afbf7e3df030bdd8a7c510&id=317a05b795&t=b&e=609b4b71a5&c=fdff8126b6)     update subscription preferences (https://useventing.us2.list-manage.com/profile?u=d07afbf7e3df030bdd8a7c510&id=317a05b795&e=609b4b71a5&c=fdff8126b6)
United States Eventing Association, Inc. . 525 Old Waterford Rd. NW . Leesburg, Virginia 20176 . USA
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.digitalkingdom.org/pipermail/house/attachments/20250917/fc84dec4/attachment-0001.htm>